Sugammadex Sodium

Base Information

• Chemical Name: Sugammadex Sodium
• CAS No.: 343306-79-6
• Deprecated CAS: 862667-16-1,1202253-72-2
• Molecular Formula: C72H104Na8O48S8
• Molecular Weight: 2178.03328
• European Community (EC) Number: 608-974-4
• UNII: ERJ6X2MXV7
• Nikkaji Number: J1.679.530E
• Wikipedia: Sugammadex
• NCI Thesaurus Code: C78123
• RXCUI: 1726987
• Mol file: 343306-79-6.mol

Synonyms:6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt;Bridion;Org 25969;Sugammadex;Sugammadex sodium

Chemical Property of Sugammadex Sodium

Chemical Property:

• PSA: 994.80000
• Density: 1.275g/cm3 (calc.)
• LogP: -18.35920
• Storage Temp.: Inert atmosphere,Room Temperature
• Hydrogen Bond Donor Count: 16
• Hydrogen Bond Acceptor Count: 56
• Rotatable Bond Count: 32
• Exact Mass: 2176.2644287
• Heavy Atom Count: 136
• Complexity: 2790

Purity/Quality:

98.5% ^*data from raw suppliers

SugammadexSodium ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])O)O)C(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
• Isomeric SMILES: C(CSC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])CSCCC(=O)[O-])O)O)C(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
• Recent ClinicalTrials: Postoperative Sugammadex After COVID-19
• Recent EU Clinical Trials: Randomized clinical trial to compare the efficacy of opioid-free versus traditional balanced anesthesia in laparoscopic colorectal surgery
• Recent NIPH Clinical Trials: Comparison of reversal with neostigmine vs. sugammadex for postoperative bowel function in patients undergoing colorectal surgery
• Description: To facilitate tracheal intubation, mechanical ventilation, and surgical access, NMB agents are frequently used as non-anesthetic adjuncts in surgical procedures. Sugammadex is able to function as a pharmacologic sink of rocuronium and vecuronium, another non-depolarizing neuromuscular blocker, without the cardiovascular adverse effects experienced with reversal agents that directly interact with the cholinergic system. The γ-cyclodextrin has been designed to enhance binding of the guest by incorporating acidic side chains to promote an electrostatic interaction with the positive nitrogen of the blocker. Starting with γ-cyclodextrin, these side chains are readily installed by first halogenating with iodine or bromine to provide a handle for nucleophilic displacement with either 3-mercaptopropionic acid in the presence of sodium hydride or with 3-mercaptopropionic acid methyl ester and cesium carbonate. The latter requires hydrolysis with sodium hydroxide to generate sugammadex sodium.
• Uses: Sugammadex Sodium is the first in a class of drugs called selective relaxant binding agents that offers improved termination of the paralytic effects of neuromuscular blocking agents and may have many potential peri-operative benefits.